VANCOUVER, British Columbia — While eye pain outcomes were similar within a week of injection of either aflibercept or ranibizumab in patients with diabetic macular edema, more anterior chamber inflammation was seen in patients receiving aflibercept, although not to a level of statistical significance.
“Anterior chamber inflammation occurred more frequently in patients receiving aflibercept compared to ranibizumab, but the difference was not statistically significant. There was no difference in the vitreous inflammation and the numbers were quite small,” Nikolas J.S. London,
Uncategorized